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The first reported case of tickborne encephalitis (TBE)
in Norway occurred in 1997. From 1997 to 2003, from zero
to two cases of human TBE have been diagnosed per year
in Norway, for a total of eight cases. Clinical TBE cases in
dogs are not reported in Norway. 
I
n Scandinavia, tickborne encephalitis (TBE) is endemic
in the coastal areas along the Baltic Sea. The first reports
of TBE from Sweden and Finland date back to1954 and
1956, but the disease was not been found in Norway until
1997. Since then, eight cases of human TBE have been
reported, and five cases have been published in a
Norwegian journal (1,2).
In a study of serum samples from dogs in Aust-Agder
County, immunoglobulin (Ig) G antibodies to TBE virus
(TBEV) were detected in 16.4% of the samples (3).
Clinical TBE cases in dogs are not reported in Norway, but
the disease is probably underdiagnosed because antibody
testing is not usually done. We present three new cases of
human TBE and summarize the clinical characteristics and
laboratory findings from all eight patients.
The Study
Patient 6 is a 62-year-old man from the town of Mandal
who was bitten by a tick; onset of symptoms began 2
weeks later. At the end of May, the patient was dizzy and
weak, had a headache, chills, and fever. He was hospital-
ized on June 11, 2002. 
The antibody from serum sample profiles showed pre-
vious infection with herpes simplex and varicella zoster
viruses. Borrelia antibodies could not be detected in serum
samples taken at 5-week intervals. IgM antibodies against
Mycoplasma pneumoniae were not detected, and virus cul-
tures were negative. Nucleic acids from herpes simplex,
varicella zoster, or enterovirus were not detected in cere-
brospinal fluid (CSF).
TBEV IgM and IgG antibodies were detected in serum
samples, with high levels of IgM (optical density [OD]
1.580 on June 13 to OD 0.899 on July 18) and high IgG
levels (13.06, OD 1.235 on June 13 to OD 1.742 on July
18). Cut-off values were 0.250 for IgM and 0.263 for IgG
on June 13 and 0.271 for IgM and 0.278 for IgG on June
18. Neutralization test antibodies in serum samples rose
from <5 in samples taken on June 13 to 10 in samples from
July 18. Symptoms gradually disappeared, and the patient
completely recovered in 2 months.
Patient 7 is a 53-year-old man who was visiting a cabin
in the coastal area near Mandal. Symptoms began at the end
of June, with fever, increasing headache, nausea, and vom-
iting. He was hospitalized on July 20, 2002. His liver
enzymes were slightly raised. Computed tomographic scan
was normal. Borrelia burgdorferi antibodies were detected
in serum, without intrathecal production of Borrelia anti-
bodies. Nucleic acids from herpes simplex virus, varicella-
zoster virus, or enterovirus were not detected in CSF. 
TBEV IgM and IgG antibodies were detected in serum
samples, with high levels of IgM (OD 2.064 on July 22;
OD 1.916 on July 30; and OD 1.499 on August 8) and ris-
ing IgG levels (OD 0.597 on July 22; OD 0.876 on July 30;
and OD 1.993 on August 8). Cut-off values were
0.277–0.280 for IgM and 0.266–0.275 for IgG).
Neutralization test antibody levels rose from <5 in serum
taken July 21 to 10 in serum from November 25.
Borderline values of TBEV antibodies were found in
spinal fluid. During the first several months after illness
onset, the patient had cognitive dysfunction but gradually
returned to work.
Patient 8 is a 74-year-old man, who lives in
Kristiansand and has a camper in Søgne. Since August
2003, he had increasing headache and from October 3,
2003 the headache was intense and accompanied by nau-
sea and vomiting. His personality was altered during these
weeks, with reduced memory about recent events in partic-
ular, irritability, and verbal aggressiveness. He was admit-
ted to the hospital on October 6, 2003. Results from
computed tomography were normal, and electroencephalo-
gram showed changes consistent with encephalitis.
Borrelia antibody levels in serum samples were low.
Intrathecal production of Borrelia antibodies could not be
detected. Nucleic acids from herpes simplex or enterovirus
were not detected in spinal fluid.
High levels of TBEV IgM (OD 1.461 on October 6
and OD 1.200 on November 5) were detected in sera
together with rising IgG levels (OD 0.652 on October 6
and OD 1.475 on November 11). Cut-off values were
0.281–0.286 for IgM and 0.259–0.265 for IgG. In spinal
fluid from October 3, intrathecal production of TBEV
antibodies could not be detected, but one month later,
intrathecal IgM was produced. During hospitalization,
the patient recovered well. After 10 to 11 days, he was
aware, and his mental situation improved considerably.
He was also able to walk on stairs. After 4 to 5 months,
he was fully recovered. 
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 12, December 2004 2241
*Sørlandet Hospital Kristiansand, Kristiansand, NorwayThe Agder counties have the highest incidence of
Borrelia infections in Norway (33 cases/100,000 persons,
1997–2003). The incidence of neuroborreliosis is 10 cases
per 100,000 persons (4). The first case of TBE in Norway
was reported in 1997 (1). The previously published clini-
cal signs and symptoms and results from these five patients
(1,2) are summarized as case 1–5, while the three new
patients are presented as patients 6–8 (Tables 1 and 2). 
The eight patients included seven men and one woman
from 42 years to 74 years of age. Biphasic courses were
described in two patients. All patients had intense
headache, seven had vertigo and nausea, and six had vom-
iting. Seven patients were hospitalized, three with reduced
consciousness, two with mental disturbances; all seven had
more or less severe neurologic abnormalities. Three had
ataxia; one had diplopia; and one had speech difficulties,
bilateral ptosis, paresis of eye and pharynx muscles, and
paresis of muscles in the left shoulder. One had an epilep-
tic seizure. All patients had fever, with temperatures from
38°C to 40°C. Serum samples were obtained from all eight
patients and had signs of inflammation with C-reactive
protein level of 10–105 mg/Land elevated leukocyte count
of 8.3–15.4 x 109/L. Seven patients underwent lumbar
puncture; CSF pleocytosis and elevated protein levels
were found in all patients. Nucleic acids from herpes sim-
plex virus, varicella-zoster virus, or enterovirus were not
detected in the spinal fluid specimens, which excludes the
most common differential diagnostic causes of encephali-
tis.
In all patients, high serum levels of TBEV IgM and IgG
antibodies were detected with enzyme-linked immunosor-
bent assay methods. In neutralization tests, serum antibody
titers increased from <5 to 10 in five of the patients, 10 to
20 in one, and 10 to 40 in one patient (1,2). Seven patients
recovered during the first 6 months. Two had cognitive
dysfunctions during the first several months. One person
still had paresis and atrophy of the shoulder muscles 1 year
later. 
Although the diagnostic tests are not absolutely specif-
ic for TBE compared to the closely related Louping ill
virus, no cases of Louping ill virus in livestock (Snorre
Stuen, pers. comm.) or human infections have been report-
ed in Norway since 1991; none of the eight patients lived
close to or worked with sheep or goats. The clinical char-
acteristics of the Norwegian patients are similar to those of
Swedish patients (5). In Sweden, the disease is caused by
TBEV subtype 1. 
All eight patients with TBE in Norway became ill after
being bitten by a tick in the coastal areas of the Agder
counties. Four had been on Tromøy Island in Aust-Agder
County before becoming ill, while one had been in
Lyngdal and three in Mandal and Søgne in Vest-Agder
County. None of the patients had been abroad in the 3
weeks before becoming ill. 
TBE was assumed not to be present in Norway. Thus,
all patients with suspicious cases of TBE may not have
been tested for antibodies to TBEV. In Agder, we have test-
ed for TBE since 1999, but the disease may still be under-
diagnosed. 
Some seroprevalence studies have been carried out.
TBEV IgG antibodies were detected in 0.3% to 0.4% of
the serum samples from persons in Agder counties. From
persons on Tromøy Island, antibodies were found in 2.4%
of serum samples, and in other coastal districts, the sero-
prevalence was 0%–11% (1,6). The number of human
serum samples tested is limited, and the vaccination status
is unknown. However, vaccination is unlikely because
Norwegians are only vaccinated against flaviviruses on
special travel indications. 
In Sweden, the incidence of human cases of TBE has
risen during the last few years, and new TBE foci have
been reported (7). During the last 2 decades, an increased
number of TBE cases have been reporting in most
European countries. Changes in the distribution of TBEV
2242 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 12, December 2004
DISPATCHESEmerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 12, December 2004 2243
have been indicated, and the Norwegian cases are from
areas where new foci have been predicted (8). 
Conclusions
In Norway, 0–2 cases of TBE were diagnosed per year
from 1997 to 2003. All patients have been bitten by a tick
in the Agder counties in southern Norway. Of the first eight
Norwegian patients, four had been on Tromøy Island in
Aust-Agder County before becoming ill. The four most
recent patients were bitten by ticks in Lyngdal, Mandal,
and Søgne in the coastal areas of Vest-Agder County. The
seroprevalence studies indicate that Tromøy and some
spots along the coast in the southernmost part of Vest-
Agder County may have a higher incidence of TBE than
the rest of the Agder counties.
Our results confirm that TBE occurs in the coastal areas
of southern Norway. Although TBE is a rare disease in
Norway, the situation has to be monitored carefully.
Further studies are required to establish guidelines for pre-
ventive measures such as vaccination.
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